Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

To assess the efficacy and toxicity of combination pegylated liposomal doxorubicin (PLD) and carboplatin against industry-standard paclitaxel and carboplatin, patients with histologically proven ovarian cancer with recurrence more than 6 months after first- or second-line platinum- and taxane-based therapies were randomly assigned by stratified blocks to CD (carboplatin area under the curve [AUC] 5 plus PLD 30 mg/m2) every 4 weeks or CP (carboplatin AUC 5 plus paclitaxel 175 mg/m2) every 3 weeks for at least 6 cycles.

Adding Another Standard to Platinum-sensitive Recurrent Ovarian Cancer